美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Innovent Biologics Inc.

39.75

0.0000

成交量：- -

成交额：- -

市值：170.93亿

市盈率：-4,835.77

高：39.75

开：39.75

低：39.75

收：39.75

52周最高：52.00

52周最低：19.15

股本：4.30亿

流通股本：4.30亿

量比：1.86

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.0082

每股收益(LYR):-0.0080

净资产收益率：8.43%

总资产收益率：2.65%

市净率：8.18

市盈率(LYR):-4,989.96

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

信达生物合作伙伴Ollin宣布IBI324头对头法瑞西单抗临床Ib期研究积极顶线数据，显示更优疗效

首个国产抗CTLA-4单抗：信达生物达伯欣®(伊匹木单抗N01注射液)获国家药品监督管理局批准上市

登顶《Nature》主刊 | 信尔美®（玛仕度肽注射液，GCG/GLP-1双靶减重降糖药物）两项III期临床研究结果背靠背同步发表

玛仕度肽中国青少年肥胖人群Ib期研究达主要终点展现出显著减重疗效和代谢获益

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IVBIY"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IVBIY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVBIY\",,,,,undefined,":{"symbol":"IVBIY","market":"US","secType":"STK","nameCN":"Innovent Biologics Inc.","latestPrice":39.75,"timestamp":1771621200000,"preClose":39.75,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":430000000,"shares":430000000,"eps":-0.00822,"marketStatus":"休市中","change":0,"latestTime":"02-20 16:00:00 EST 延时","open":39.75,"high":39.75,"low":39.75,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.00822,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":4,"exchange":"PINK LIMITED","adjPreClose":39.75,"volumeRatio":1.8633563519954686},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVBIY\",,,,,undefined,":{"symbol":"IVBIY","floatShares":430000000,"roa":"2.65%","roe":"8.43%","lyrEps":-0.007966,"volumeRatio":1.8633563519954686,"shares":430000000,"dividePrice":0,"high":39.75,"amplitude":0,"preClose":39.75,"low":39.75,"week52Low":19.15,"pbRate":"8.18","psRate":"10.33","week52High":52,"institutionHeld":0,"latestPrice":39.75,"eps":-0.00822,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.00822,"open":39.75,"prevYearClose":41.75,"prevWeekClose":39.75,"prevMonthClose":39.75,"prevQuarterClose":41.75,"fiveDayClose":39.75,"twentyDayClose":41.8,"sixtyDayClose":45.184},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IVBIY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-28","symbol":"IVBIY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IVBIY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IVBIY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4483,"buy":0.4483,"hold":0.1034,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4483,"analysts":29,"updateTime":1767848400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IVBIY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2602348564","title":"信达生物合作伙伴Ollin宣布IBI324头对头法瑞西单抗临床Ib期研究积极顶线数据，显示更优疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2602348564","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602348564?lang=zh_cn&edition=fundamental","pubTime":"2026-01-09 08:00","pubTimestamp":1767916800,"startTime":"0","endTime":"0","summary":"OLN324相较法瑞西单抗在视网膜积液消退的速度和幅度上展现出的差异极具说服力，并具有明确的临床意义。\" Ollin Biosciences联合创始人兼首席执行官Jason Ehrlich医学博士表示：\"OLN324是首个也是目前唯一一个在随机、头对头临床研究中显示出解剖学疗效优于市场领先药物法瑞西单抗的治疗方案。在安全性方面，OLN324显示出良好的安全性特征。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4859017_ZH59017_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","LU2097828631.EUR","BK1161","BK1583","LU0502904849.HKD","BK1589","LU2097828557.USD","LU2488822045.USD","LU0455707207.USD","LU2242644610.SGD","BK4139","LU1969619763.USD","LU2328871848.SGD","IVBIY","LU2097828714.EUR","HK0000165453.HKD","LU2097828474.EUR","LU2097828805.USD"],"gpt_icon":0},{"id":"2594076236","title":"首个国产抗CTLA-4单抗：信达生物达伯欣®(伊匹木单抗N01注射液)获国家药品监督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2594076236","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594076236?lang=zh_cn&edition=fundamental","pubTime":"2025-12-25 17:59","pubTimestamp":1766656740,"startTime":"0","endTime":"0","summary":"达伯欣的新药上市申请获中国国家药品监督管理局批准，联合达伯舒用于可手术切除的IIB-III期微卫星高度不稳定型或错配修复缺陷结肠癌患者的新辅助治疗。安全性方面，伊匹木单抗N01联合信迪利单抗组相较直接手术组未显著增加额外的安全性风险。我们很高兴在信达生物高质量高效的临床开发推动下，达伯欣  作为中国首个本土创新的抗CTLA-4抑制剂成功获批上市，为中国可手术切除MSI-H/dMMR结肠癌患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4853695_ZH53695_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2097828474.EUR","LU2328871848.SGD","LU2097828714.EUR","LU0502904849.HKD","LU0455707207.USD","LU2097828805.USD","LU2242644610.SGD","BK1583","LU2097828557.USD","LU2097828631.EUR","BK1161","HK0000165453.HKD","LU1969619763.USD","BK4139","BK1589","IVBIY","LU2488822045.USD","01801"],"gpt_icon":0},{"id":"2592442959","title":"登顶《Nature》主刊 | 信尔美®（玛仕度肽注射液，GCG/GLP-1双靶减重降糖药物）两项III期临床研究结果背靠背同步发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2592442959","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592442959?lang=zh_cn&edition=fundamental","pubTime":"2025-12-18 08:00","pubTimestamp":1766016000,"startTime":"0","endTime":"0","summary":"此次论文通过《自然》加速预览机制得以快速上线，再次印证国际顶级期刊对于玛仕度肽两项重磅研究的认可。信达生物制药集团综合管线首席研发官钱镭博士表示：\"信尔美是全球首个获批上市的GCG/GLP-1双靶药物，目前减重和糖尿病适应症均已获批。继其减重注册研究今年五月份发表于《新英格兰杂志》后，本次两项降糖注册研究DREAMS-1和DREAMS-2的成果再次以背靠背形式同步登上《自然》杂志，并以加速预览形式发表。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4849560_ZH49560_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["III","LU2097828714.EUR","LU2097828557.USD","BK1589","LU2242644610.SGD","LU2097828631.EUR","01801","BK4134","LU2097828474.EUR","BK1583","LU2097828805.USD","LU0502904849.HKD","LU0455707207.USD","BK1161","BK4139","GLP","LU2488822045.USD","LU1969619763.USD","LU2328871848.SGD","HK0000165453.HKD","BK4590","BK4144","IVBIY"],"gpt_icon":0},{"id":"2590526115","title":"玛仕度肽中国青少年肥胖人群Ib期研究达主要终点展现出显著减重疗效和代谢获益","url":"https://stock-news.laohu8.com/highlight/detail?id=2590526115","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590526115?lang=zh_cn&edition=fundamental","pubTime":"2025-12-12 08:00","pubTimestamp":1765497600,"startTime":"0","endTime":"0","summary":"目前国内没有任何批准用于儿童、青少年的减重药物，玛仕度肽青少年肥胖的III期注册临床将于近期启动。此项研究结果令人倍感鼓舞，表明玛仕度肽为中国青少年肥胖人群提供了一种兼具强效减重疗效与良好安全性的全新治疗方案。玛仕度肽已在多项临床研究中展现出优秀的减重和降糖疗效，以及降低腰围、血脂、血压、血尿酸、肝酶及肝脏脂肪含量，以及改善胰岛素敏感性，带来多重代谢获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4844686_ZH44686_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2097828714.EUR","BK1161","BMI","01801","BK4157","LU1969619763.USD","LU2328871848.SGD","BK4139","LU2488822045.USD","HK0000165453.HKD","BK1589","LU2097828805.USD","LU0502904849.HKD","LU2097828557.USD","LU2097828474.EUR","BK1583","OXM","LU0455707207.USD","IVBIY","LU2097828631.EUR","LU2242644610.SGD","BK4202"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IVBIY\",params:#limit:6,delay:false,,,undefined,":[]}}